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www.haematologica.org/content/103/12/2088 In the POLLUX study, daratumumab plus lenalidomide/dexametha-sone significantly reduced risk of progression/death versus lenalido-mide/dexamethasone alone in relapsed/refractory multiple myeloma.
We provide one additional year of follow up and include the effect on
minimal residual disease and in clinically relevant subgroups. After 25.4
months of follow up, daratumumab plus lenalidomide/dexamethasone
prolonged progression-free survival versus lenalidomide/dexamethasone
alone (median not reached vs. 17.5 months; hazard ratio, 0.41; 95% con-
fidence interval, 0.31-0.53; P<0.0001). The overall response rate was
92.9% versus 76.4%, and 51.2% versus 21.0% achieved a complete
response or better, respectively (both P<0.0001). At the 10–5 sensitivity
threshold, 26.2% versus 6.4% were minimal residual disease–negative,
respectively (P<0.0001). Post hoc analyses of clinically relevant patient
subgroups demonstrated that progression-free survival was significantly
prolonged for daratumumab plus lenalidomide/dexamethasone versus
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ABSTRACT
Introduction  
Novel therapeutics approved during the last decade for
relapsed or refractory multiple myeloma (RRMM), includ-
ing proteasome inhibitors (PIs) and immunomodulatory
drugs (IMiDs), are now standard of care treatments.1-3
However, patients eventually relapse and subpopulations
such as those with high-risk cytogenetic abnormalities
may not achieve the same benefits as standard-risk
patients.4 Treatment choices must be based on patient fac-
tors (comorbidities, frailty, preferences), disease factors
(burden, molecular risk), and treatment factors (prior ther-
apies, refractoriness, and toxicity). 
Daratumumab is a human monoclonal antibody target-
ing CD38, a cell surface receptor highly expressed on mul-
tiple myeloma (MM) cells,5,6 that exerts its effects via
direct on-tumor and immunomodulatory mechanisms of
action.7-11 Daratumumab is approved in many countries as
monotherapy for patients with heavily treated RRMM.12,13
In combination with standard of care regimens, including
bortezomib/dexamethasone (Vd; CASTOR study)14 and
lenalidomide/dexamethasone (Rd; POLLUX study),15 dara-
tumumab significantly prolonged progression-free sur-
vival (PFS) and deepened responses in patients with
RRMM. This led to regulatory approval in many countries
for patients with ≥1 prior line of therapy.16,17
In the prespecified interim analysis of POLLUX, after a
median follow up of 13.5 months, daratumumab in com-
bination with Rd (D-Rd) resulted in a 63% reduction in
the risk of disease progression or death, significantly high-
er overall response rates (ORRs; 92.9% vs. 76.4%), and
significantly higher minimal residual disease (MRD)-nega-
tivity rates at multiple sensitivity thresholds versus Rd.15
To identify patients who may benefit more from D-Rd
treatment, we conducted subgroup analyses of POLLUX
after a longer follow up of 25.4 months. The efficacy of 
D-Rd versus Rd was compared according to the number of
prior lines of therapy received, prior IMiD exposure,
bortezomib refractoriness, treatment-free interval after
previous treatment line, and cytogenetic risk. We also
assessed the ability of daratumumab to drive deep clinical
responses beyond complete responses (CRs) through
assessment of MRD.
Methods
Study Design
POLLUX is an ongoing randomized, open-label, multicenter,
phase 3 study conducted in patients with RRMM (clinicaltrials.gov
identifier: 02076009). An independent ethics committee or institu-
tional review board at each site approved the trial. The study pro-
tocol was conducted in accordance with the principles of the
Declaration of Helsinki and the International Conference on
Harmonisation Good Clinical Practice guidelines. The study
design and primary results have been previously published.15
Briefly, eligible patients had progressive disease according to
International Myeloma Working Group (IMWG) criteria18,19 dur-
ing or after their last regimen and had received and responded to
≥1 line of prior therapy; lenalidomide-refractory patients were
ineligible. Patients were randomized 1:1 to Rd (lenalidomide: 
25 mg orally on Days 1-21 of each 28-day cycle; dexamethasone:
40 mg orally weekly) with or without daratumumab (16 mg/kg
intravenously weekly for 8 weeks, every 2 weeks for 16 weeks,
and then every 4 weeks) until progression.  
Endpoints and Assessments
The primary efficacy endpoint was PFS, and secondary efficacy
endpoints included ORR, rates of very good partial response
(VGPR) or better and CR or better, MRD, time to response, and
overall survival. 
This exploratory, post hoc, secondary analysis examined patient
populations according to prior lines of therapy received (1, 2-3, 
1-3), prior treatment exposure (bortezomib, lenalidomide, and
thalidomide), refractoriness to bortezomib, time since last therapy
(>12 months, ≤12 months, >6 months, and ≤6 months prior to ran-
domization), and cytogenetic risk. Numbers of prior lines of ther-
apy were determined by investigators according to the IMWG
consensus guidelines.19 Treatment-free interval was defined as the
duration between the end date of the last line of prior therapy and
randomization. Cytogenetic abnormalities were determined with
CD138+ selected cells at the screening visit prior to randomization
by centralized next-generation sequencing. The presence of 1 or
more of t(4;14), t(14;16), or del17p (utilizing >50% deletion cut-
off) defined a patient as high risk. Standard-risk cytogenetic status
was assigned to those not meeting the high-risk criteria. Due to
limitations with sample quality or quantity, and because cytoge-
netic evaluation was mandated mid-study, cytogenetic risk was
not evaluated in all patients. PFS, ORR, and MRD negativity at
sensitivity thresholds of 10–5 and 10–6 were assessed for each sub-
group. PFS based on MRD and cytogenetic risk status was also
examined. Health-related quality of life (HRQoL) was assessed
using the EuroQol 5-Dimension Questionnaire (EQ-5D-5L) and
the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core-30 (EORTC QLQ-C30).  
Minimal Residual Disease
MRD was assessed (blinded to treatment group) at the time of
suspected CR (i.e., CR/stringent CR or VGPR with suspected
interference20,21), and at 3 and 6 months after suspected CR for
patients who maintained this response. The MRD-negativity rate
per treatment arm was determined as the proportion of patients
with negative MRD at any time point after the first dose and com-
pared using the likelihood-ratio test. 
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lenalidomide/dexamethasone regardless of number of prior lines of therapy. Patients previously treated
with lenalidomide or thalidomide and those refractory to bortezomib received similar benefits (all
P<0.01). Treatment benefit with daratumumab plus lenalidomide/dexamethasone was maintained in
high-risk patients (median progression-free survival 22.6 vs. 10.2 months; hazard ratio, 0.53; 95% confi-
dence interval, 0.25-1.13; P=0.0921) and patients with treatment-free intervals of >12 and ≤12 months
and >6 and ≤6 months. No new safety signals were observed. In relapsed/refractory multiple myeloma
patients, daratumumab plus lenalidomide/dexamethasone continued to improve progression-free sur-
vival and deepen responses versus lenalidomide/dexamethasone. Trial Registration: clinicaltrials.gov identi-
fier: 02076009. 
Additional details on assessments for safety, MRD, cytogenetic
risk, and HRQoL and statistical analyses are provided in the
Appendix.
Results 
Of 569 enrolled patients in POLLUX, 286 were assigned
to D-Rd and 283 to Rd (Appendix Figure 1). Baseline patient
demographics and prior treatment history were generally
balanced and have been previously reported.15 Additional
baseline clinical and cytogenetic characteristics are sum-
marized in Table 1. The median (range) duration of study
treatment was 24.5 (0-32.7) months in the D-Rd group and
16.0 (0.20-32.2) months in the Rd group. 
At the clinical cut-off on March 7, 2017, the median
(range) duration of follow up was 25.4 (0-32.7) months.
Consistent with the primary analysis, D-Rd improved PFS
compared with Rd (median not reached [NR] vs. 17.5
months; hazard ratio [HR], 0.41; 95% confidence interval
[CI], 0.31-0.53; P<0.0001), with 24-month PFS rates of
68.0% versus 40.9%, respectively (Figure 1A). In the
response-evaluable population, D-Rd (n=281) compared
with Rd alone (n=276) significantly improved the ORR
(92.9% vs. 76.4%, respectively; P<0.0001 [Table 2]), and
rates of ≥VGPR and ≥CR (Appendix Table 1). Stringent CRs
were achieved by 26.0% and 8.7% of patients receiving
D-Rd and Rd, respectively (Appendix Table 1). Overall sur-
vival data remain immature, and the final analysis is
planned after 330 events are observed.
D-Rd significantly improved PFS in RRMM patients
who received several prior lines of therapy, a population
for whom more effective therapies are needed. In patients
who received 1 prior line of therapy, D-Rd significantly
prolonged PFS compared with Rd (D-Rd, n=149; Rd,
n=146; median NR vs. 19.6 months; HR, 0.39; 95% CI,
0.26-0.58, P<0.0001 [Figure 1B, Appendix Figure 2A]), with
24-month PFS rates of 70.3% and 45.0%, respectively. A
similar benefit was observed in patients who received 2 to
3 prior lines of therapy (Figure 1B, Appendix Figure 2B).
ORR was also significantly improved in patients treated
with 1 prior line of therapy (D-Rd, n=147; Rd, n=142;
93.2% vs. 80.3%; P=0.0003 [Table 2]) and 2 to 3 prior lines
of therapy (D-Rd, n=120; Rd, n=115; 95.0% vs. 73.9%;
P<0.0001 [Table 2]). It is considered preferable for MM
patients who relapse to switch drug classes for subsequent
therapy,22 and, in bortezomib-refractory patients, D-Rd
significantly prolonged PFS compared with Rd (D-Rd,
n=59; Rd, n=58; median 26.1 vs. 11.3 months; HR, 0.46;
95% CI, 0.26-0.80; P=0.0051 [Figure 1B]), with 24-month
PFS rates of 60.0% and 29.7%,  respectively, and
improved ORR (D-Rd, n=57; Rd, n=56; 87.7% vs. 67.9%;
P=0.0113 [Table 2]). 
Patients with high-risk cytogenetic status have had his-
torically poor outcomes, but, regardless of cytogenetic risk
status, D-Rd improved outcomes compared with Rd
(Figures 1B and 2, Table 2). PFS was longer for D-Rd-treat-
ed (n=28) versus Rd-treated patients (n=37) with high cyto-
genetic risk (median 22.6 vs. 10.2 months; HR, 0.53; 95%
CI, 0.25-1.13; P=0.0921; 24-month PFS rate, 48.1% vs.
31.7%), and significantly longer for patients with stan-
dard-risk disease (D-Rd, n=133; Rd, n=113; median NR vs.
18.5 months; HR, 0.30; 95% CI, 0.20-0.47; P<0.0001; 
24-month PFS rate, 74.3% vs. 40.0% [Figures 1B and 2]).
With D-Rd versus Rd, significantly higher ORRs were
observed for both high-risk (D-Rd, n=27; Rd, n=36; 85.2%
vs. 66.7%; P=0.0435) and standard-risk patients (D-Rd,
n=132; Rd, n = 111; 94.7% vs. 82.0%; P=0.0004 [Table 2]).
Further subgroup analyses determined that the clinical
benefit of daratumumab was maintained in patients
regardless of prior lines of therapy received (1-3), prior
treatment exposure (thalidomide or lenalidomide), or time
since last therapy (≤12, >12, ≤6, or >6 months [Figure 1B,
Table 2, Appendix Figure 2C]).
Although D-Rd was associated with a significant treat-
ment benefit in subpopulations that received their last line
of prior therapy either ≤12 or >12 months before random-
ization into the study (Figure 1B, Table 2), the proportion
of patients who remained progression-free and alive at 24
months was smaller among patients who relapsed earlier
in both the D-Rd (63.6% vs. 72.4%) and Rd (29.2% vs.
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Table 1. Baseline demographic and clinical characteristics.
Characteristic                                                   D-Rd                 Rd
                                                                      (n=286)          (n=283)
Age, years
Median (range)                                                     65 (34-89)         65 (42-87)
Median (range) time from diagnosis, years          3.48                     3.95
                                                                                     (0.4-27.0)          (0.4-21.7)
ECOG performance-status, n (%)
0                                                                                 139 (48.6)         150 (53.0)
1                                                                                 136 (47.6)         118 (41.7)
2                                                                                   11 (3.8)             15 (5.3)
Cytogenetic profile, n (%)a
n                                                                                     161                      150
Standard risk                                                         133 (82.6)         113 (75.3)
High risk                                                                  28 (17.4)           37 (24.7)
t(4;14)                                                                   16 (9.9)            21 (14.0)
t(14;16)                                                                  1 (0.6)               3 (2.0)
del17p                                                                    13 (8.1)             13 (8.7)
Prior lines of therapy, n (%)
Median (range)                                                      1 (1-11)              1 (1-8)
1                                                                               149 (52.1)         146 (51.6)
2 to 3                                                                       123 (43.0)         118 (41.7)
Time since last prior line of therapy, n (%)
>12 months                                                            140 (49.0)         149 (52.7)
≤12 months                                                            146 (51.0)         134 (47.3)
>6 months                                                              187 (65.4)         188 (66.4)
≤6 months                                                               99 (34.6)           95 (33.6)
Prior ASCT, n (%)                                                    180 (62.9)         180 (63.6)
Prior PI, n (%)                                                          245 (85.7)         242 (85.5)
Bortezomib                                                             241 (84.3)         238 (84.1)
Prior IMiD, n (%)                                                    158 (55.2)         156 (55.1)
Lenalidomide                                                          50 (17.5)           50 (17.7)
Thalidomide                                                           122 (42.7)         125 (44.2)
Prior IMiD + PI, n (%)                                           125 (43.7)         125 (44.2)
Refractory to bortezomib, n (%)                          59 (20.6)           58 (20.5)
Refractory to last line of therapy, n (%)            80 (28.0)           76 (26.9)
D-Rd: daratumumab/lenalidomide/dexamethasone; Rd: lenalidomide/dexametha-
sone; ECOG: Eastern Cooperative Oncology Group; ASCT: autologous stem cell trans-
plantation; PI: proteasome inhibitor; IMiD: immunomodulatory drug. aCentral 
next-generation sequencing. High-risk patients had any of t(4;14), t(14;16), or del17p.
Standard-risk patients had an absence of high-risk abnormalities. 
51.4%) treatment groups. However, the ORR and PFS in
patients with a shorter treatment-free interval was more
severely impacted in patients treated with Rd compared
with D-Rd (Figure 1B, Table 2).  
MRD status was evaluated to determine the ability of
daratumumab to generate deeper responses in patients
achieving conventional CR. The IMWG established
MRD-negative criteria requiring evaluation by next-gener-
ation sequencing to be conducted at a minimum sensitiv-
ity threshold of 10–5.23 At this threshold, of the ITT popu-
lation, 26.2% of patients treated with D-Rd achieved
MRD negativity compared with 6.4% of patients who
received Rd (P<0.000001 [Table 2]). Consistent findings
were also observed for D-Rd versus Rd at a sensitivity
threshold of 10–6 (12.9% vs. 2.8%; P=0.000003). D-Rd gen-
erated deeper responses and higher MRD-negativity rates
than Rd in all subgroups evaluated (Table 2), including
patients who received 1 prior line of therapy (D-Rd,
n=149; Rd, n=146; 10–5: 25.5% vs. 8.2%; P=0.000053; 10–6:
10.1% vs. 4.8%; P=0.08134) and 2 to 3 prior lines of ther-
apy (D-Rd, n=123; Rd, n=118; 10–5: 27.6% vs. 4.2%;
P<0.000001; 10–6: 16.3% vs. 0.8%; P=0.000003), patients
who were bortezomib refractory (D-Rd, n=59; Rd, n=58;
10–5: 20.3% vs. 6.9%; P=0.0308; 10–6: 10.2% vs. 3.4%;
P=0.1410), and patients who had high-cytogenetic risk at
a sensitivity threshold of 10–5 (D-Rd, n=28; Rd, n=37;
21.4% vs. 0.0%, P=0.0009) and 10–6 (D-Rd, n=28; Rd,
n=37; 14.3% vs. 0.0%, P=0.0078 [Table 2]). PFS was pro-
longed in patients who achieved MRD negativity com-
pared with MRD-positive patients in both treatment arms
(Figure 3A-B). D-Rd also significantly prolonged PFS com-
pared with Rd in patients with MRD-positive status at the
10–5 and 10–6 sensitivity thresholds (P<0.001 [Figure 3A-B]).
At the time of the analysis, the majority of patients main-
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Figure 1. (A) PFS in the ITT popu-
lation and (B) a forest plot sum-
mary of PFS HRs in subgroups
by prior lines, prior therapies,
treatment-free intervals. Kaplan-
Meier analysis of PFS among
patients in the ITT population.
aTreatment-free interval was
defined as the duration between
the end date of the last line of
prior therapy and randomization.
bHigh-risk patients had any of
t(4;14), t(14;16), or del17p as
assessed by next generation
sequencing. cStandard-risk
patients had an absence of high-
risk abnormalities.  PFS: progres-
sion-free survival; ITT: intent-to-
treat; HR: hazard ratio; D-Rd:
daratumumab/lenalidomide/dex
amethasone; Rd: lenalidomide/
dexamethasone; CI: confidence
interval; NR: not reached; TFI:
treatment-free interval; std: stan-
dard. 
A
B
No. of progression or
death events/total no.
Median PFS (months)
tained MRD-negative status; patients will continue to be
assessed annually.
The safety profile remained unchanged from the pri-
mary analysis, with no new safety signals reported in
either treatment group with longer follow up (Table 3).
The most common treatment-emergent adverse events
(≥15%) of any grade included neutropenia, anemia,
thrombocytopenia, diarrhea, fatigue, upper respiratory
tract infection, cough, constipation, muscle spasms,
nasopharyngitis, and nausea (Table 3). The most common
grade 3/4 treatment-emergent adverse events (≥5%)
included neutropenia, febrile neutropenia, anemia, throm-
bocytopenia, lymphopenia, diarrhea, fatigue, and pneu-
monia (Table 3). The percentage of patients with adverse
events leading to treatment discontinuation was similar
between groups (12.0% for D-Rd, 12.8% for Rd). The
most common adverse events (≥1%) leading to treatment
discontinuation in D-Rd compared with Rd included
pneumonia (1.4% vs. 0.7%), pulmonary embolism (0% vs.
1.1%), general physical health deterioration (1.1% vs.
0%), and renal failure (0.4% vs. 1.1%), respectively. 
The incidence of second primary malignancies between
the D-Rd (n=283) and Rd (n=281) groups was the same
(5.7% vs. 5.7%), consistent with previous observations
that had no notable differences.15 The proportion of
patients who received transfusions while on study drug
was also similar between the D-Rd and Rd groups (24.4%
vs. 25.3%). 
There was no decline in HRQoL measures with the addi-
tion of daratumumab to Rd. Statistically significant differ-
ences in the change from baseline were observed in favor of
D-Rd at Weeks 48 and 56 with the Utility Score and at
Weeks 40, 48, and 56 with the Visual Analog Scale Score of
the EQ-5D-5L questionnaire. With the EORTC QLQ-C30
Global Health Status Score, statistically significant differ-
ences in the change from baseline were observed in favor of
D-Rd at Weeks 40, 48, 52, 68, 84, and 116. However, these
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Figure 2. PFS by cytogenetic risk status. Cytogenetic risk was assessed via next-
generation sequencing. High-risk patients had any of t(4;14), t(14;16), or del17p.
Standard-risk patients had an absence of high-risk abnormalities. PFS: progres-
sion-free survival; D-Rd: daratumumab/lenalidomide/dexamethasone; Rd:
lenalidomide/dexamethasone; HR: hazard ratio; CI: confidence interval.
Table 2. ORR and MRD based on prior treatment history.
# of patients ORR, n (%)a # of patients MRD, n (%)b
in group in group
10–5 10–6
Subgroup D-Rd Rd D-Rd Rd Pc D-Rd Rd D-Rd Rd Pd D-Rd Rd Pd
ITT 281 276 261 (92.9) 211 (76.4) <0.0001 286 283 75 (26.2) 18 (6.4) <0.000001 37 (12.9) 8 (2.8) 0.000003
Prior lines of therapy
1 147 142 137 (93.2) 114 (80.3) 0.0003 149 146 38 (25.5) 12 (8.2) 0.000053 15 (10.1) 7 (4.8) 0.081340
2-3 120 115 114 (95.0) 85 (73.9) <0.0001 123 118 34 (27.6) 5 (4.2) <0.000001 20 (16.3) 1 (0.8) 0.000003
1-3 267 257 251 (94.0) 199 (77.4) <0.0001 272 264 72 (26.5) 17 (6.4) <0.0001 35 (12.9) 8 (3.0) <0.0001
Prior therapy
Bortezomib 237 232 218 (92.0) 175 (75.4) <0.0001 241 238 63 (26.1) 18 (7.6) <0.000001 32 (13.3) 8 (3.4) 0.000051
Lenalidomide 50 47 42 (84.0) 32 (64.0) 0.0233 50 50 13 (26.0) 2 (4.0) 0.0012 7 (14.0) 2 (4.0) 0.0729
Thalidomide 119 123 109 (91.6) 87 (70.7) <0.0001 122 125 26 (21.3) 6 (4.8) <0.0001 16 (13.1) 2 (1.6) 0.0002
Refractory to bortezomib 57 56 50 (87.7) 38 (67.9) 0.0113 59 58 12 (20.3) 4 (6.9) 0.0308 6 (10.2) 2 (3.4) 0.1410
Treatment-free interval   
≤12 months 143 131 129 (90.2) 87 (66.4) <0.0001 146 134 34 (23.3) 7 (5.2) <0.0001 16 (11.0) 2 (1.5) 0.0006
>12 months 138 145 132 (95.7) 124 (85.5) 0.0038 140 149 41 (29.3) 11 (7.4) <0.0001 21 (15.0) 6 (4.0) 0.0010
≤6 months 98 92 87 (88.8) 57 (62.0) <0.0001 99 95 21 (21.2) 6 (6.3) 0.0021 8 (8.1) 2 (2.1) 0.0514
>6 months 183 184 174 (95.1) 154 (83.7) 0.0004 187 188 54 (28.9) 12 (6.4) <0.0001 29 (15.5) 6 (3.2) <0.0001
Cytogenetic riske
Highf 27 36 23 (85.2) 24 (66.7) 0.0435 28 37 6 (21.4) 0 (0) 0.0009 4 (14.3) 0 (0) 0.0078
Standard 132 111 125 (94.7) 91 (82.0) 0.0004 133 113 42 (31.6) 13 (11.5) 0.0001 20 (15.0) 6 (5.3) 0.0109
ORR: overall response rate; MRD: minimal residual disease; D-Rd: daratumumab/lenalidomide/dexamethasone; Rd: lenalidomide/dexamethasone; ITT: intent-to-treat. Data are based on com-
puterized algorithm. aResponse-evaluable population. bITT population. cP value was generated using the Cochran-Mantel-Haenszel c2 test. dP value was generated using the likelihood-ratio c2
test. eBiomarker risk-evaluable population. fIncludes subjects who have either del17p, t(14;16), t(4;14) or a combination of these.
improvements did not last beyond 3 consecutive assess-
ments in either questionnaire. No significant differences for
median time to improvement (6.6 months vs. 6.5 months;
HR, 1.03; 95% CI, 0.81-1.30; P=0.820) were reported for
EORTC QLQ-C30 Global Health Status Scores in the D-Rd
and Rd groups. Similarly, no significant differences in medi-
an time to improvement were observed between treatment
groups for either the EQ-5D-5L Utility Score (6.6 months vs.
10.2 months; HR, 1.23; 95% CI, 0.97-1.57; P=0.089) or
Visual Analog Scale Score (6.9 months vs. 9.3 months; HR,
1.14; 95% CI, 0.89-1.45; P=0.283). 
Discussion
These updated analyses with nearly one further year of
follow up reinforce the initial findings of deep and durable
responses achieved with D-Rd in RRMM patients.15 The
benefit of D-Rd over Rd was consistently maintained
across patients who received 1 or 2 to 3 prior lines of ther-
apy, and the risk of progression or death was reduced by
>60%. D-Rd was also superior to Rd regardless of prior
treatment exposure (i.e., lenalidomide, thalidomide,
bortezomib-refractory), time since last therapy, and cyto-
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Figure 3. PFS by MRD at sensitivity
thresholds of (A) 10–5 and (B) 10–6.
Kaplan-Meier estimates of PFS among
patients in the intent-to-treat popula-
tion. MRD-negative status was evaluat-
ed at sensitivity thresholds of 10–5 and
10–6 using bone marrow aspirate sam-
ples that were prepared using Ficoll
and analyzed by the clonoSEQTM assay.
PFS: progression-free survival; MRD:
minimal residual disease; D-Rd: dara-
tumumab/lenalidomide/dexametha-
sone; Rd: lenalidomide/dexametha-
sone; HR: hazard ratio; CI: confidence
interval.
A
B
genetic risk status. As one of the first studies to prospec-
tively assess MRD in a phase 3 trial of RRMM, 
MRD-negativity rates were also significantly higher with
D-Rd across all patient subgroups, including patients with
high cytogenetic risk. These findings reinforce observa-
tions that highlight the depth, durability, and robustness
of responses achieved with daratumumab-based regi-
mens.24 
These findings compare favorably with other studies of
IMiD-containing regimens with subgroup analyses based
on prior lines of therapy and/or prior treatment exposure
(Appendix Table 2). In a large phase 3 study (ASPIRE) of
carfilzomib-Rd (KRd) compared with Rd alone, a consis-
tent PFS benefit was observed with KRd versus Rd among
patients who received 1 and 2 to 3 prior lines of therapy.25
Prespecified PFS subgroup analyses showed a modest ben-
efit with KRd over Rd for patients who previously
received lenalidomide and patients nonresponsive to
bortezomib in any previous regimen.26 The magnitude of
benefit for KRd versus Rd was similar in patients with
early disease relapse (≤12 months from starting the first
prior regimen; ORR: 79% vs. 61%).27 In a phase 3 study of
elotuzumab (ELOQUENT-2), the PFS benefit in combina-
tion with Rd was maintained among patients who
received 2 to 3 prior lines of therapy or had prior exposure
to bortezomib but not among patients who received 1
prior line of therapy or prior lenalidomide.28,29 Ixazomib in
combination with lenalidomide and dexamethasone in
the phase 3 TOURMALINE-MM1 study demonstrated a
modest PFS benefit versus Rd in patients who received 1 or
2 prior lines, were previously treated with an IMiD or a PI,
and were refractory to their last line of therapy; interest-
ingly, patients who received 3 prior lines of therapy
demonstrated an HR of 0.37.30
D-Rd improved responses, including MRD negativity in
patients with high-risk cytogenetic status, suggesting that
targeting CD38 in combination with Rd may improve
outcomes for this challenging-to-treat population.
Moreover, despite the small number of patients with
high-risk disease, D-Rd demonstrated significantly higher
MRD-negativity rates compared with standard-risk
patients receiving Rd. While PFS was not statistically dif-
ferent between D-Rd versus Rd for patients with high-risk
disease, a numerical improvement in PFS was observed in
high-risk patients who received D-Rd versus Rd. As the
magnitude of benefit for D-Rd was lower among high-
risk patients, these findings suggest that while D-Rd is
able to provide improvements in efficacy, it is not able to
overcome the greater risk of progression and poor out-
comes associated with high-risk disease. Although cross-
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Table 3. Most common all grade (≥15%) and grade 3/4 (≥5%) treatment-emergent adverse events in the safety population. 
D-Rd Rd
(n=283) (n=281)
Event, n (%) All grade Grade 3/4 All grade Grade 3/4
Total 281 (99.3) 251 (88.7) 274 (97.5) 216 (76.9)
Hematologic
Neutropenia 172 (60.8) 153 (54.1) 127 (45.2) 112 (39.9)
Febrile neutropenia 17 (6.0) 17 (6.0) 8 (2.8) 8 (2.8)
Anemia 104 (36.7) 44 (15.5) 109 (38.8) 60 (21.4)
Thrombocytopenia 81 (28.6) 39 (13.8) 87 (31.0) 44 (15.7)
Lymphopenia 18 (6.4) 15 (5.3) 16 (5.7) 11 (3.9)
Nonhematologic
Diarrhea 144 (50.9) 20 (7.1) 89 (31.7) 9 (3.2)
Fatigue 103 (36.4) 18 (6.4) 85 (30.2) 10 (3.6)
Upper respiratory tract infection 105 (37.1) 4 (1.4) 74 (26.3) 4 (1.4)
Cough 91 (32.2) 1 (0.4) 40 (14.2) 0 (0.0)
Constipation 88 (31.1) 3 (1.1) 74 (26.3) 2 (0.7)
Muscle spasms 81 (28.6) 3 (1.1) 59 (21.0) 4 (1.4)
Nasopharyngitis 84 (29.7) 0 (0.0) 54 (19.2) 0 (0.0)
Nausea 76 (26.9) 5 (1.8) 50 (17.8) 2 (0.7)
Insomnia 67 (23.7) 4 (1.4) 61 (21.7) 4 (1.4)
Pyrexia 67 (23.7) 7 (2.5) 36 (12.8) 5 (1.8)
Dyspnea 59 (20.8) 12 (4.2) 35 (12.5) 2 (0.7)
Back pain 58 (20.5) 6 (2.1) 53 (18.9) 5 (1.8)
Pneumonia 58 (20.5) 34 (12.0) 42 (14.9) 24 (8.5)
Bronchitis 53 (18.7) 6 (2.1) 46 (16.4) 7 (2.5)
Edema peripheral 53 (18.7) 2 (0.7) 43 (15.3) 4 (1.4)
Vomiting 52 (18.4) 3 (1.1) 19 (6.8) 4 (1.4)
Asthenia 51 (18.0) 10 (3.5) 43 (15.3) 8 (2.8)
Headache 43 (15.2) 0 (0.0) 22 (7.8) 0 (0.0)
D-Rd: daratumumab/lenalidomide/dexamethasone; Rd: lenalidomide/dexamethasone.
study comparisons should be performed with caution,
smaller differences in PFS and ORR between standard-
and high-risk patients in the CASTOR study in patients
treated with daratumumab and Vd were observed.31
Daratumumab-based combinations that include both a PI
and an IMiD may further improve efficacy in patients
with high-risk disease. 
Prolonged treatment with D-Rd or Rd did not uncover
new safety concerns, and the incidences of second pri-
mary malignancies were balanced between study arms.
While certain adverse events, such as cough, dyspnea, and
pneumonia occurred more frequently with daratumumab,
the percentage of patients that discontinued treatment due
to adverse events was similar between groups (12.0% for
D-Rd, 12.8% for Rd). Additionally, patients in the D-Rd
group were treated for longer, with a median duration of
24.5 months versus 16.0 months in the Rd group, which
likely contributed to the increase in rates for certain
adverse events. Finally, the addition of a third drug to the
standard of care Rd regimen did not have a negative effect
on HRQoL. 
Several limitations of the study should be noted. First,
although balanced between treatment arms, only a subset
of patient samples was collected for central cytogenetic
testing as outlined in the Methods. Second, not all eligible
patients with suspected CR or CR had available MRD
data, and these patients were therefore conservatively
classified as MRD positive. Based on the experiences
obtained from this phase 3 study, continuous improve-
ments in MRD testing are being implemented across
ongoing and future daratumumab studies in multiple
myeloma. Finally, based on the limitations of post hoc
analyses, the findings presented here require further con-
firmation in future studies prospectively assessing the effi-
cacy of D-Rd in these clinically relevant patient popula-
tions.
In summary, these updated secondary subgroup analy-
ses highlight the benefit of combining daratumumab with
the standard of care regimen Rd in RRMM across exam-
ined subgroups. The addition of daratumumab to Rd
drove deep responses, as shown by achievement of MRD
negativity in many patients. These results suggest that 
D-Rd is a highly effective and well-tolerated regimen that
may be recommended for RRMM after first relapse and
beyond. 
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